Preoperative 5-Day Radiotherapy for Soft Tissue Sarcoma
Part of paid clinical trials in Charleston, South Carolina.
- Sponsor
- Medical University of South Carolina
- Study ID
- NCT06905132
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- Soft Tissue Sarcoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Hypofractionated Radiation Therapy — RADIATIONParticipants will receive preoperative 5-day HFRT (30Gy/5fx once daily over consecutive weekdays) followed by "standard of care" wide local excision 2-6 weeks later.
Study Details
The purpose of this research study is to preserve healthy tissue around the cancer on the arm(s) and/or leg(s) using Hypofractionated radiotherapy, while treating the cancer and preventing it from spreading to other areas of the body.
Key Dates
- Start date
- Apr 1, 2025
- Status verified
- Mar 2026
- Primary completion
- Mar 27, 2029
- Completion
- Mar 27, 2030
Study Design
- Enrollment
- 40 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Hypofractionated Radiation Therapy
Primary Outcome Measure
HFRT Safety [ Time Frame: 6 months ]
Central Contacts
- HCC Clinical Trials Office843-792-9321
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Medical University of South Carolina | Charleston | South Carolina | 29401 | Jennifer Harper, MD |
Find similar trials in Charleston, SC
By research site
Related Studies
- LMWH vs Aspirin for VTE Prophylaxis in Orthopaedic OncologyPHASE4 · Enrolling By Invitation · Massachusetts General Hospital · Los Angeles, California
- Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway AlterationPHASE2 · Recruiting · Medical College of Wisconsin · Jacksonville, Florida
- Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue SarcomaPHASE1/PHASE2 · Recruiting · Memorial Sloan Kettering Cancer Center · New York, New York
- B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)PHASE1 · Recruiting · St. Jude Children's Research Hospital · Memphis, Tennessee